News | Published:

Sandoz sues FDA over delay in first biogeneric approval

Officials at the generic branch of Novartis filed a rare type of lawsuit with the US District Court that may affect how the FDA regulates biogenerics.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Related links

Related links

Web links

Sandoz

Rights and permissions

Reprints and Permissions

About this article

Further reading